SINOPHARM Financial Statements From 2010 to 2024
| X2S1 Stock | EUR 13.10 0.20 1.55% |
Check SINOPHARM GROUP financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SINOPHARM GROUP's main balance sheet or income statement drivers, such as , as well as many indicators such as . SINOPHARM financial statements analysis is a perfect complement when working with SINOPHARM GROUP Valuation or Volatility modules.
SINOPHARM |
SINOPHARM GROUP 15ON Company Shares Owned By Institutions Analysis
SINOPHARM GROUP's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current SINOPHARM GROUP Shares Owned By Institutions | 0.01 % |
Most of SINOPHARM GROUP's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SINOPHARM GROUP 15ON is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.01% of SINOPHARM GROUP 15ON are shares owned by institutions. This is 99.98% lower than that of the Healthcare sector and 99.99% lower than that of the Medical Distribution industry. The shares owned by institutions for all Germany stocks is 99.97% higher than that of the company.
SINOPHARM GROUP 15ON Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SINOPHARM GROUP's current stock value. Our valuation model uses many indicators to compare SINOPHARM GROUP value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SINOPHARM GROUP competition to find correlations between indicators driving SINOPHARM GROUP's intrinsic value. More Info.SINOPHARM GROUP 15ON is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for SINOPHARM GROUP 15ON is roughly 3.62 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SINOPHARM GROUP's earnings, one of the primary drivers of an investment's value.About SINOPHARM GROUP Financial Statements
SINOPHARM GROUP stakeholders use historical fundamental indicators, such as SINOPHARM GROUP's revenue or net income, to determine how well the company is positioned to perform in the future. Although SINOPHARM GROUP investors may analyze each financial statement separately, they are all interrelated. For example, changes in SINOPHARM GROUP's assets and liabilities are reflected in the revenues and expenses on SINOPHARM GROUP's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in SINOPHARM GROUP 15ON. Please read more on our technical analysis and fundamental analysis pages.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GROUP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.
Currently Active Assets on Macroaxis
Other Information on Investing in SINOPHARM Stock
SINOPHARM GROUP financial ratios help investors to determine whether SINOPHARM Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SINOPHARM with respect to the benefits of owning SINOPHARM GROUP security.